Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Daiichi Sankyo
Chubb
Healthtrust
Harvard Business School
Federal Trade Commission
Argus Health
US Department of Justice
Novartis

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017581

« Back to Dashboard

NDA 017581 describes NAPROSYN, which is a drug marketed by Atnahs Pharma Us and is included in two NDAs. It is available from four suppliers. Additional details are available on the NAPROSYN profile page.

The generic ingredient in NAPROSYN is naproxen. There are forty-two drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the naproxen profile page.
Summary for 017581
Tradename:NAPROSYN
Applicant:Atnahs Pharma Us
Ingredient:naproxen
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 017581
Medical Subject Heading (MeSH) Categories for 017581
Suppliers and Packaging for NDA: 017581
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NAPROSYN naproxen TABLET;ORAL 017581 NDA Genentech, Inc. 0004-6316 0004-6316-01 100 TABLET in 1 BOTTLE, PLASTIC (0004-6316-01)
NAPROSYN naproxen TABLET;ORAL 017581 NDA Cameron Pharmaceuticals, LLC 42494-403 42494-403-05 500 TABLET in 1 BOTTLE, PLASTIC (42494-403-05)

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength375MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG
Approval Date:Apr 15, 1982TE:ABRLD:Yes

Expired US Patents for NDA 017581

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
AstraZeneca
Argus Health
Citi
Queensland Health
Healthtrust
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot